For research use only. Not for therapeutic Use.
Terconazole（Cat No.:R023386）is a triazole antifungal agent widely utilized in pharmaceutical research and treatment of fungal infections. It works by inhibiting the synthesis of ergosterol, a key component of fungal cell membranes, leading to increased membrane permeability and cell death. Terconazole is particularly effective against Candida species, making it a prominent choice for treating vulvovaginal candidiasis. Known for its broad-spectrum antifungal activity and favorable safety profile, Terconazole is also studied for its pharmacokinetics and resistance patterns to develop improved antifungal therapies.
| Catalog Number | R023386 |
| CAS Number | 67915-31-5 |
| Synonyms | (±)-Terconazole; Fungistat; Gyno-Terazol; NSC 331942; R 42470; Terazol; Terazol Cream & Suppositories; Tercospor; Termayazole; Triaconazole; cis-1-[4-[[2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-(1-meth |
| Molecular Formula | C₂₆H₃₁Cl₂N₅O₃ |
| Purity | ≥95% |
| Storage | -20°C |
| IUPAC Name | 1-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-propan-2-ylpiperazine |
| InChI | InChI=1S/C26H31Cl2N5O3/c1-19(2)31-9-11-32(12-10-31)21-4-6-22(7-5-21)34-14-23-15-35-26(36-23,16-33-18-29-17-30-33)24-8-3-20(27)13-25(24)28/h3-8,13,17-19,23H,9-12,14-16H2,1-2H3/t23-,26-/m0/s1 |
| InChIKey | BLSQLHNBWJLIBQ-OZXSUGGESA-N |
| SMILES | CC(C)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=NC=N4)C5=C(C=C(C=C5)Cl)Cl |
| Reference | </br>1:Novel lecithin-integrated liquid crystalline nanogels for enhanced cutaneous targeting of terconazole: development, in vitro and in vivo studies. Elnaggar YS, Talaat SM, Bahey-El-Din M, Abdallah OY.Int J Nanomedicine. 2016 Oct 25;11:5531-5547. eCollection 2016. PMID: 27822033 Free PMC Article</br>2:Fabrication of novel ultradeformable bilosomes for enhanced ocular delivery of terconazole: In vitro characterization, ex vivo permeation and in vivo safety assessment. Abdelbary AA, Abd-Elsalam WH, Al-Mahallawi AM.Int J Pharm. 2016 Nov 20;513(1-2):688-696. doi: 10.1016/j.ijpharm.2016.10.006. Epub 2016 Oct 4. PMID: 27717916 </br>3:A randomized clinical trial of the efficacy and safety of terconazole vaginal suppository versus oral fluconazole for treating severe vulvovaginal candidiasis. Li T, Zhu Y, Fan S, Liu X, Xu H, Liang Y.Med Mycol. 2015 Jun;53(5):455-61. doi: 10.1093/mmy/myv017. Epub 2015 Apr 15. PMID: 25877666 </br>4:Enantiomeric separation of ketoconazole and terconazole antifungals by electrokinetic chromatography: Rapid quantitative analysis of ketoconazole in pharmaceutical formulations. Castro-Puyana M, Crego AL, Marina ML.Electrophoresis. 2005 Oct;26(20):3960-8. PMID: 16217826 </br>5:Terconazole cream for non-Candida albicans fungal vaginitis: results of a retrospective analysis. Sood G, Nyirjesy P, Weitz MV, Chatwani A.Infect Dis Obstet Gynecol. 2000;8(5-6):240-3. PMID: 11220485 Free PMC Article</br>6:[Effectiveness and safety of ciclopirox olamine 1% vaginal cream versus terconazole 0.8% vaginal cream in the treatment of genital candidiasis]. García Figueroa RG, Sauceda L, Ramírez Palacios D, Cruz Talonia F, Romero Cabello R.Ginecol Obstet Mex. 2000 Apr;68:154-9. Spanish. PMID: 10824446 </br>7:Fatal toxic epidermal necrolysis associated with use of terconazole vaginal suppository. Searles GE, Tredget EE, Lin AN.J Cutan Med Surg. 1998 Oct;3(2):85-7. No abstract available. PMID: 9822781 </br>8:In vitro susceptibility of clinical yeast isolates to fluconazole and terconazole. Cooper CR Jr, McGinnis MR.Am J Obstet Gynecol. 1996 Dec;175(6):1626-31. PMID: 8987951 </br>9:Prevention of recurrent vaginal candidiasis with weekly terconazole cream. Stein GE, Mummaw NL, Schooley SL.Ann Pharmacother. 1996 Oct;30(10):1080-3. PMID: 8893111 </br>10:Fever and leukocytosis related to terconazole vaginal suppository. Hyder SS, Manjon JE, Gantz NM.South Med J. 1994 Jul;87(7):762-3. PMID: 8023214 |
